Intercept Pharmaceuticals Financials
Based on the key indicators related to Intercept Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Intercept Pharmaceuticals is not in a good financial situation at the moment. It has a very high risk of going through financial straits in April.
Intercept |
Understanding current and past Intercept Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Intercept Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Intercept Pharmaceuticals' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Intercept Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Intercept Pharmaceuticals. Check Intercept Pharmaceuticals' Beneish M Score to see the likelihood of Intercept Pharmaceuticals' management manipulating its earnings.
Intercept Pharmaceuticals Stock Summary
Intercept Pharmaceuticals competes with Viking Therapeutics, Terns Pharmaceuticals, Akero Therapeutics, Madrigal Pharmaceuticals, and TG Therapeutics. Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company was incorporated in 2002 and is headquartered in New York, New York. Intercept Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 437 people.Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US45845P1084 |
Business Address | 10 Hudson Yards, |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.interceptpharma.com |
Phone | 646 747 1000 |
Currency | USD - US Dollar |
Intercept Pharmaceuticals Key Financial Ratios
Return On Equity | -0.64 | |||
Return On Asset | -0.0723 | |||
Target Price | 19.0 | |||
Number Of Employees | 341 | |||
Beta | 0.88 |
Intercept Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Intercept Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Intercept Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Intercept Pharmaceuticals competition to find correlations between indicators driving Intercept Pharmaceuticals's intrinsic value. More Info.Intercept Pharmaceuticals is rated below average in return on equity category among its peers. It is rated fifth overall in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Intercept Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Other Consideration for investing in Intercept Stock
If you are still planning to invest in Intercept Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intercept Pharmaceuticals' history and understand the potential risks before investing.
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |